Richard failed to answer the question that was put to him in...

Richard failed to answer the question that was put to him in relation to why so few dogs were trialed. Pretty poor response.

Also, the questions I emailed to JP Equities were not put to the panel. Obviously picked and chose which questions they wanted to answer.

One of the first slides said human trials in 2021. Considering they did the cap raise in 2019 that's a big gap. And they're still procrastinating about which cancers to consider in human trials. What have they been doing for the past 12 - 18 months?? Surely they would have narrowed it down.

Other than the positive Covid results, a pretty lame presentation in my view.